From DMDI “Drug Metabolism and Drug Interactions” to DMPT “Drug Metabolism and Personalized Therapy”

Artikel in diesem Heft

1. Frontmatter
2. Editorial
3. From DMDI “Drug Metabolism and Drug Interactions” to DMPT “Drug Metabolism and Personalized Therapy”
4. Review
5. Clinical drug-drug interactions: focus on venlafaxine
6. Reviews in Population Pharmacogenomics
7. Pharmacogenetics in Central American healthy volunteers: interethnic variability
8. Genomic biomarkers related to drug response in Venezuelan populations
9. Originial Articles
10. No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia
11. Chloral hydrate, through biotransformation to dichloroacetate, inhibits maleylacetoacetate isomerase and tyrosine catabolism in humans
12. Effect of rifampin on the pharmacokinetics of bosutinib, a dual Src/Abl tyrosine kinase inhibitor, when administered concomitantly to healthy subjects
13. Minor contribution of biliary excretion in lithium elimination in rats
14. Case Report
15. Fatal hyperkalemia following succinylcholine administration in a child on oral propranolol